Introduction: More than 200 cases of cancer have been diagnosed and breast cancer is the most common invasive cancer and the second leading cause of cancer mortality in women. There are several treatments for breast cancer. The failure of many therapeutic options is referred to drugs resistance and side effects of drugs and therefore, identify new tools and specific platforms with the lowest side effects and high effectiveness remains a main challenge among interested researchers. Stem cells are a multipotent population of cells with unique biological characteristics and thereby, it was demonstrated to be a potent tool for cancer therapy. Focal adhesions play key roles in cell motility and migration. Of note, overexpression of focal adhesions in many human cancer types was reported. The aim of this study was the evaluation of the therapeutic effects of human amniotic mesenchymal stromal cells (hAMSCs) on MDA-MB-231 breast cancer cells migration through down regulation of Fibronectin.
Methods: we employed a co-culture system using 6 well plates transwell and after 72h, hAMSCs-treated MDA-MB-231 breast cancer cells were analyzed by using western blot method. Also, the cell shape and motility of cells were analyzed.
Results: Our results showed that the hAMSCS secretome has therapeutic effects on cancer cells migration through down regulation of Fibronectin.
Conclusion: Our present study revealed that Fibronectin may be considered as a potential target by hAMSCs secretome in breast cancer therapy. However, the molecular mechanisms are not clear and thereby, more experiments will be required.
Keywords: MDA-MB-231 breast cancer cells, hAMSCs, Fibronectin expression, Cell migration